With the CANOVA results in mind, would you continue using venetoclax in patients with multiple myeloma with t(11;14)?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question • Multiple Myeloma

Answer from: Medical Oncologist at Academic Institution

TL;DR - I will still be using venetoclax for t(11;14) myeloma in the way that I have been doing so for some time, which is in combination with other active myeloma agents. I prefer venetoclax 400 mg daily, in combination with either carfilzomib 56 mg/m2 weekly or daratumumab SQ.Now the long version:...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
I have little to add to @Ben Derman's excellent re...

Medical Oncologist at Memorial Sloan Kettering Cancer Center
I agree with @Ben and @Rahul. The trial does not i...

Related Questions